Cargill’s EpiCor postbiotic ingredient health claims licensed by Health Canada

News
Article

The claims focus on support for immune and digestive health.

Photo © AdobeStock.com/elenabsl

Photo © AdobeStock.com/elenabsl

Cargill (Minneapolis) announced that Health Canada has licensed 10 health claims for the company’s EpiCor postbiotic ingredient as a Natural Health Product. The health claims focus on support for immune and digestive health.

The claims are based on a daily EpiCor dose of 500 mg in adults aged 18 and older and are backed by more than a dozen published clinical studies, the company says. The claims include:

  • Helps to reduce the incidence of cold and flu symptoms (during the winter months)
  • Helps to reduce the symptoms of seasonal allergies such as nasal stuffiness/congestion
  • Helps relieve nasal stuffiness/congestion associated with seasonal allergies
  • Helps to maintain immune function
  • An antioxidant that helps to support good health
  • Source of antioxidant(s)/provides antioxidant(s)
  • Helps support intestinal/gastrointestinal health
  • Helps to improve occasional mild to moderate bloating/distension
  • Helps to improve occasional mild to moderate feeling of fullness
  • Occasionally helps to improve stool consistency

In a press release, Justin Green, PhD, director of scientific affairs for EpiCor, added, “This news, from one of the world’s leading health agencies, affirms the significant body of science behind EpiCor…”

Related Videos
© 2024 MJH Life Sciences

All rights reserved.